
    
      OBJECTIVES:

        -  Determine the objective response rate in patients with metastatic renal cell carcinoma
           treated with gemcitabine and capecitabine.

        -  Determine the duration of overall and progression-free survival of patients treated with
           this regimen.

        -  Determine the toxicity of this regimen in these patients.
    
  